801-P: TRIM—Teen Obesity and GLP-1 Receptor Agonists—Insights from a Systematic Review, Meta-analysis, and Drug-Wise Network Meta-analysis

Introduction 95% CI -7.08 to -1.35; 95% PI -14.44 to 6.01; 11 RCTs; 818 participants; high quality evidence]. There is also reduction in BMI and waist circumference. The results are consistent in subgroup analyses for coexisting T2D. There is greatest efficacy with Semaglutide followed by Exenatide, Liraglutide, and Lixisenatide Figure. Conclusion: GLP1RAs reduce weight-related outcomes in adolescents with Semaglutide being the most efficacious. RCTs with direct comparisons, pragmatic study design, longer follow-up (to generate or verify safety signals), and adiposity-related outcomes are needed to further guide the usage and choice of GLP1RAs. Disclosure M. Shamim: None. A. Rastogi: None. S. Singh: None. S. Chenchula: None. V. Ganesh: None. K. Tiwari: None. S. Varthya: None. P. Dwivedi: None. R. Shukla: None. P. Rao: None. P. Satapathy: None. A. Patil: None. U. Amin: None. T. Roy: None. A. Gandhi: None. R. Sah: None.